Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Lymphoid 1

Conditions

Neoplasm Metastasis 36Leukemia, Myeloid, Acute 32Multiple Myeloma 27Lymphoma 23Breast Neoplasms 18Prostatic Neoplasms 17Pancreatic Neoplasms 17Colorectal Neoplasms 17Lymphoma, Large B-Cell, Diffuse 15Burkitt Lymphoma 15Myelodysplastic Syndromes 14Leukemia, Lymphocytic, Chronic, B-Cell 14Triple Negative Breast Neoplasms 12Ovarian Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Melanoma 11Lung Neoplasms 11Sarcoma 10Lymphoma, T-Cell 9Glioma 9Carcinoma, Non-Small-Cell Lung 9Neuroblastoma 8Neoplasms 8Fallopian Tube Neoplasms 8Carcinoma, Renal Cell 8Squamous Cell Carcinoma of Head and Neck 7Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 7Leukemia, Biphenotypic, Acute 7Endometrial Neoplasms 7

Interventions

pembrolizumab 6avelumab 6Nivolumab 5Specimen Handling 4Magnetic Resonance Spectroscopy 3Biopsy 3prednylidene 2lutetium Lu 177 dotatate 2deltacortene 2Prednisone 2Ipilimumab 2CTLA-4 Antigen 2talimogene laherparepvec 1lenvatinib 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1cemiplimab 1aldesleukin 1Tacrolimus 1Sirolimus 1Saline Solution 1Radiotherapy 1Radiosurgery 1MAPRE1 protein, human 1Lutetium-177 1Laparoscopy 1Exercise Test 1Cyclophosphamide 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Merkel Cell × Biopsy × 90 days × Clear all
NCT02978625 2026-05-13

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
68 enrolled
DermatologicLymphoid

Microcystic adnexal carcinoma, Adenocarcinoma, Papillary, Carcinoma, Basal Cell, Carcinoma, Basosquamous, Mycosis Fungoides, Paget Disease, Extramammary, Sezary Syndrome, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Carcinoma, Signet Ring Cell, Muir-Torre Syndrome, Eccrine Porocarcinoma

NCT05896839 2026-05-13

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
16 enrolled
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT05947500 2026-05-13

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
50 enrolled
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡